BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36061307)

  • 1. Comprehensive Analysis of Gene Signatures of m6ARNA Methylation Regulators in Lung Adenocarcinoma and Development of a Risk Scoring System.
    Gao C; Li H; Ma W; Zhang Q; Liu C; Liu L; Zhuang J; Sun C
    J Immunol Res; 2022; 2022():7519838. PubMed ID: 36061307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of N6-Methyladenosine Regulators on LAG3 and Immune Infiltrates in Lung Adenocarcinoma.
    Wang N; Xu Y; Jin L; Wang X; Wu S; Wang Y; Zhao J; Zhou F; Ge H
    Dis Markers; 2022; 2022():1829528. PubMed ID: 36051357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value and Genome Signature of m6A/m5C Regulated Genes in Early-Stage Lung Adenocarcinoma.
    Tian L; Wang Y; Tian J; Song W; Li L; Che G
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel m5C/m6A-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Ma Y; Yang J; Ji T; Wen F
    Front Genet; 2022; 13():990623. PubMed ID: 36246622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and Prognostic Significance of m6A-Related Genes in Lung Adenocarcinoma.
    Zhang Y; Liu X; Liu L; Li J; Hu Q; Sun R
    Med Sci Monit; 2020 Feb; 26():e919644. PubMed ID: 32086933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comprehensive Analysis of the Relationship between m6A Methylation Patterns and Immune Microenvironment in Lung Adenocarcinoma].
    Ke J; Cui J; Yang X; Du X; Ma B; Yu L
    Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):311-322. PubMed ID: 35599007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of m6A modification patterns and m6A-related lncRNAs as potential biomarkers in lung adenocarcinoma.
    Wang S; Gu X; Xu D; Liu B; Qin K; Yuan X
    Environ Toxicol; 2024 Apr; 39(4):2285-2303. PubMed ID: 38148718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
    Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
    Front Immunol; 2021; 12():724741. PubMed ID: 34335635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA-Binding Protein IGF2BP1 Associated With Prognosis and Immunotherapy Response in Lung Adenocarcinoma.
    Liu J; Li Z; Cheang I; Li J; Zhou C
    Front Genet; 2022; 13():777399. PubMed ID: 35154270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene signatures of 6-methyladenine regulators in women with lung adenocarcinoma and development of a risk scoring system: a retrospective study using the cancer genome atlas database.
    Gao C; Zhuang J; Li H; Liu C; Zhou C; Liu L; Feng F; Sun C
    Aging (Albany NY); 2021 Jan; 13(3):3957-3968. PubMed ID: 33428597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four m6A RNA Methylation Gene Signatures and Their Prognostic Values in Lung Adenocarcinoma.
    Wang Y; Zhao X; Li J; Wang X; Hu W; Zhang X
    Technol Cancer Res Treat; 2022; 21():15330338221085373. PubMed ID: 35343834
    [No Abstract]   [Full Text] [Related]  

  • 14. ECE2 is a prognostic biomarker associated with m6A modification and involved in immune infiltration of lung adenocarcinoma.
    Zhang YH; Zeng J; Liu XS; Gao Y; Kui XY; Liu XY; Zhang Y; Pei ZJ
    Front Endocrinol (Lausanne); 2022; 13():1013238. PubMed ID: 36299451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N6-methyladenosine (m6A) regulator expression pattern correlates with the immune landscape in lung adenocarcinoma.
    Wan RJ; Bai L; Jiang J; Hu CP; Chen Q; Zhao BR; Zhang Y; Li YY
    Gene; 2022 Aug; 836():146639. PubMed ID: 35700805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel M6A-Related Genes Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma.
    Wang X; Zhao C; Huang D; Liu Z; Liu M; Lin F; Lu Y; Jia J; Lin L; Lin X; Li H; Chen Z
    Front Immunol; 2022; 13():923533. PubMed ID: 35860262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Link between m6A modification and infiltration characterization of tumor microenvironment in lung adenocarcinoma.
    Yang S; Li K; Zhang J; Liu J; Liu L; Tan Y; Xu C
    Exp Biol Med (Maywood); 2023 Dec; 248(23):2273-2288. PubMed ID: 38166412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer.
    Liu X; Ma C; Liu H; Sun Z; Luo J
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2803-2814. PubMed ID: 35596010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value and multiomic features of m6A-related risk signature in lung adenocarcinoma.
    Wang X; Yu Q; Yu H; Wang Y; Sun L; Yu L; Cui H; Yang H
    Am J Transl Res; 2022; 14(8):5379-5393. PubMed ID: 36105012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.